Mesa Laboratories (NASDAQ:MLAB) CFO John Sakys Sells 2,827 Shares of Stock

Mesa Laboratories, Inc. (NASDAQ:MLAB) CFO John Sakys sold 2,827 shares of the company’s stock in a transaction dated Monday, June 22nd. The shares were sold at an average price of $89.50, for a total transaction of $253,016.50. Following the completion of the sale, the chief financial officer directly owned 19,785 shares of the company’s stock, valued at $1,770,757.50. This represents a 12.50% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

John Sakys also recently made the following trade(s):

• On Tuesday, June 16th, John Sakys sold 1,223 shares of Mesa Laboratories stock. The stock was sold at an average price of $101.27, for a total transaction of $123,853.21.

Mesa Laboratories Stock Performance

NASDAQ:MLAB opened at $91.97 on Wednesday. The company has a debt-to-equity ratio of 0.78, a current ratio of 1.72 and a quick ratio of 1.29. The firm has a market capitalization of $507.67 million, a price-to-earnings ratio of 76.64 and a beta of 0.94. The company’s 50-day moving average is $101.87 and its two-hundred day moving average is $91.09. Mesa Laboratories, Inc. has a 1-year low of $55.45 and a 1-year high of $113.99.

Mesa Laboratories (NASDAQ:MLAB) last posted its quarterly earnings results on Wednesday, May 27th. The medical instruments supplier reported $1.53 earnings per share for the quarter, missing the consensus estimate of $1.78 by ($0.25). The firm had revenue of $63.72 million during the quarter, compared to analysts’ expectations of $65.21 million. Mesa Laboratories had a net margin of 2.69% and a return on equity of 20.96%. During the same period last year, the company earned ($1.31) EPS.

Mesa Laboratories Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Monday, June 15th. Investors of record on Friday, May 29th were given a $0.16 dividend. This represents a $0.64 annualized dividend and a yield of 0.7%. The ex-dividend date was Friday, May 29th. Mesa Laboratories’s dividend payout ratio is presently 53.33%.

Institutional Investors Weigh In On Mesa Laboratories

Institutional investors have recently made changes to their positions in the stock. Royal Bank of Canada boosted its position in shares of Mesa Laboratories by 1.2% during the 1st quarter. Royal Bank of Canada now owns 30,772 shares of the medical instruments supplier’s stock worth $3,652,000 after purchasing an additional 353 shares during the period. Jacobs Levy Equity Management Inc. purchased a new stake in Mesa Laboratories in the first quarter valued at approximately $335,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in Mesa Laboratories by 4.9% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 3,068 shares of the medical instruments supplier’s stock worth $364,000 after purchasing an additional 143 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in Mesa Laboratories by 3.6% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 19,977 shares of the medical instruments supplier’s stock worth $2,370,000 after purchasing an additional 685 shares in the last quarter. Finally, American Century Companies Inc. boosted its position in shares of Mesa Laboratories by 1.5% during the second quarter. American Century Companies Inc. now owns 13,431 shares of the medical instruments supplier’s stock worth $1,265,000 after buying an additional 194 shares during the period. 90.60% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Separately, Weiss Ratings downgraded Mesa Laboratories from a “sell (d+)” rating to a “sell (d)” rating in a research report on Wednesday, June 3rd. Two equities research analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Mesa Laboratories presently has an average rating of “Reduce” and an average target price of $94.00.

Mesa Laboratories Company Profile

Mesa Laboratories, Inc (NASDAQ: MLAB) is a global provider of instrumentation products designed for critical process monitoring, testing and calibration. Headquartered in Lakewood, Colorado, the company serves a diverse set of end markets including healthcare, pharmaceutical, food and beverage, energy and industrial sectors. With a focus on precision measurement and validation, Mesa Laboratories helps customers ensure regulatory compliance, product safety and operational efficiency across complex manufacturing and sterilization processes.

The company’s product portfolio encompasses biological and chemical indicators for sterilization process validation, digital data loggers and sensors for environmental monitoring, and optical gas analyzers with sample-conditioning solutions for oil, gas and petrochemical applications.